Serum amyloid A1 mRNA (SAA1 mRNA)

Serum amyloid A1 mRNA encodes the major acute-phase apolipoprotein serum amyloid A1, which is strongly and rapidly upregulated in response to inflammatory cytokines such as IL-1β, IL-6, and TNF-α[1][3][5]. Transcription of SAA1 is controlled by multiple inflammation-related transcription factors including NF-κB, STAT3, and C/EBP[1]. Elevated SAA1 mRNA indicates acute inflammation and is a reliable clinical indicator and biomarker for diverse inflammatory diseases, metabolic disorders, and advanced malignancy[1][5]. The mRNA is translated into a pre-protein, which is further processed to mature SAA1. Persistently elevated expression, and resulting SAA1 protein, contributes to amyloid A (AA) amyloidosis through tissue deposition of proteolytic fragments[1][2][4]. Targeting the mRNA of SAA1 remains uncommon in therapy, though modulation at this level could theoretically alter protein production and subsequent amyloid risk.

Other names

Serum amyloid A mRNASAA mRNASAA1 transcriptacute-phase SAA mRNASAA1 pre-mRNA